| A phase Ib study of the dual PI3K/mTOR inhibitor dactolisib (BEZ235) combined with everolimus in patients with advanced solid malignancies TM Wise-Draper, G Moorthy, MA Salkeni, NA Karim, HE Thomas, ... Targeted oncology 12, 323-332, 2017 | 108 | 2017 |
| Lipopolysaccharide impairs blood–brain barrier P-glycoprotein function in mice through prostaglandin-and nitric oxide-independent pathways MA Salkeni, JL Lynch, T Otamis-Price, WA Banks Journal of Neuroimmune Pharmacology 4, 276-282, 2009 | 76 | 2009 |
| Safety and efficacy of T-DM1 plus neratinib in patients with metastatic HER2-positive breast cancer: NSABP foundation trial FB-10 J Abraham, AJ Montero, RC Jankowitz, MA Salkeni, JH Beumer, ... Journal of Clinical Oncology 37 (29), 2601-2609, 2019 | 71 | 2019 |
| Detection of EGFRvIII mutant DNA in the peripheral blood of brain tumor patients MA Salkeni, A Zarzour, TY Ansay, CM McPherson, RE Warnick, O Rixe, ... Journal of neuro-oncology 115, 27-35, 2013 | 71 | 2013 |
| MicroRNAs 206 and 21 Cooperate To Promote RAS–Extracellular Signal-Regulated Kinase Signaling by Suppressing the Translation of RASA1 and SPRED1 SB Sharma, CC Lin, MK Farrugia, SL McLaughlin, EJ Ellis, KM Brundage, ... Molecular and cellular biology 34 (22), 4143-4164, 2014 | 65 | 2014 |
| Kruppel-like pluripotency factors as modulators of cancer cell therapeutic responses MK Farrugia, DB Vanderbilt, MA Salkeni, JM Ruppert Cancer research 76 (7), 1677-1682, 2016 | 61 | 2016 |
| Regulation of anti-apoptotic signaling by Kruppel-like factors 4 and 5 mediates lapatinib resistance in breast cancer MK Farrugia, SB Sharma, CC Lin, SL McLaughlin, DB Vanderbilt, ... Cell death & disease 6 (3), e1699-e1699, 2015 | 48 | 2015 |
| Combination of eribulin and Aurora A inhibitor MLN8237 prevents metastatic colonization and induces cytotoxic autophagy in breast cancer VK Kozyreva, AA Kiseleva, RJ Ice, BC Jones, YV Loskutov, F Matalkah, ... Molecular cancer therapeutics 15 (8), 1809-1822, 2016 | 35 | 2016 |
| Randomized phase II study of ramucirumab or icrucumab in combination with capecitabine in patients with previously treated locally advanced or metastatic breast cancer LT Vahdat, R Layman, DA Yardley, W Gradishar, MA Salkeni, AA Joy, ... The oncologist 22 (3), 245-254, 2017 | 23 | 2017 |
| Interleukin-10 in cancer immunotherapy: from bench to bedside MA Salkeni, A Naing Trends in Cancer 9 (9), 716-725, 2023 | 18 | 2023 |
| Metastatic breast cancer: Endocrine therapy landscape reshaped MA Salkeni, SJ Hall Avicenna Journal of Medicine 7 (04), 144-152, 2017 | 16 | 2017 |
| Sapanisertib Plus Exemestane or Fulvestrant in Women with Hormone Receptor–Positive/HER2-Negative Advanced or Metastatic Breast Cancer B Lim, DA Potter, MA Salkeni, P Silverman, TC Haddad, F Forget, ... Clinical Cancer Research 27 (12), 3329-3338, 2021 | 13 | 2021 |
| NSABP FB-10: Phase Ib dose-escalation trial evaluating trastuzumab emtansine (T-DM1) with neratinib (N) in women with metastatic HER2+ breast cancer (MBC). J Abraham, S Puhalla, WM Sikov, AJ Montero, MA Salkeni, W Razaq, ... Journal of Clinical Oncology 36 (15_suppl), 1027-1027, 2018 | 13 | 2018 |
| The stem cell phenotype of aggressive breast cancer cells NV Margaryan, H Hazard-Jenkins, MA Salkeni, MB Smolkin, JA Coad, ... Cancers 11 (3), 340, 2019 | 12 | 2019 |
| BEZ235 in combination with everolimus for advanced solid malignancies: Preliminary results of a phase Ib dose-escalation study. MA Salkeni, O Rixe, N Abdel Karim, S Ogara, M Feiler, G Moorthy, ... Journal of Clinical Oncology 31 (15_suppl), e13518-e13518, 2013 | 9 | 2013 |
| Neu Perspectives, Therapies, and Challenges for Metastatic HER2-Positive Breast Cancer MA Salkeni, W Rizvi, K Hein, GM Higa Breast Cancer: Targets and Therapy, 539-557, 2021 | 8 | 2021 |
| A Phase Ib study of the dual PI3K/mTOR inhibitor dactolisib (BEZ235) combined with everolimus in patients with advanced solid malignancies. Target Oncol. 2017; 12 (3): 323–32 TM Wise-Draper, G Moorthy, MA Salkeni, NA Karim, HE Thomas, ... DOI: https://doi. org/10.1007/s11523-017-0482-9, 323-332, 0 | 6 | |
| Resistance to immunotherapy: mechanisms and means for overcoming MA Salkeni, JY Shin, JL Gulley Immunotherapy, 45-80, 2021 | 5 | 2021 |
| Abstract PD1-09: Phase 2 safety and efficacy results of TAK-228 in combination with exemestane or fulvestrant in postmenopausal women with ER-positive/HER2-negative metastatic … JR Diamond, D Potter, M Salkeni, P Silverman, T Haddad, F Forget, ... Cancer Research 79 (4_Supplement), PD1-09-PD1-09, 2019 | 4 | 2019 |
| Prognostic factors in breast cancer patients evaluated by positron-emission tomography/computed tomography before neoadjuvant chemotherapy M Farrugia, S Wen, G Jacobson, M Salkeni World Journal of Nuclear Medicine 17 (04), 275-280, 2018 | 4 | 2018 |
